Physician profile
Madison Webb
NPI 1346779394
$64,134.15
in general payments reported to CMS, 2019-2025
30 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $3,154 · 2023: $6,510 · 2024: $21K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $9,117 · Food and Beverage: $7,457 · Travel and Lodging: $4,931 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,904.00 |
| Consulting Fee | $9,117.00 |
| Food and Beverage | $7,456.97 |
| Travel and Lodging | $4,931.24 |
| Education | $288.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38,746.43 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $9,478.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $4,565.15 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $2,280.71 | 2022-2025 | Sotyktu |
| Abbvie INC. | $1,855.64 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,435.50 | 2025 | |
| Incyte Corporation | $1,391.24 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $821.21 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Scientific Affairs, LLC | $576.61 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $558.13 | 2021-2025 | |
| Galderma Laboratories, L.P. | $352.63 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $307.76 | 2023-2025 | Zoryve |
| Ucb, INC. | $305.73 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $291.38 | 2021-2025 | |
| Leo Pharma INC. | $287.52 | 2021-2025 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $185.38 | 2022-2025 | Otezla, Otezla |
| Journey Medical Corporation | $173.67 | 2022-2025 | |
| Pfizer INC. | $166.65 | 2022-2025 | |
| Dermavant Sciences, INC. | $65.35 | 2023 | Vtama |
| Almirall LLC | $48.29 | 2022-2024 | Seysara |
| Hologic Sales and Service, LLC | $44.90 | 2025 | Aptima |
| Convatec INC. | $38.46 | 2024-2025 | |
| Organon LLC | $29.32 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $24.63 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.41 | 2025 | Cabtreo, Jublia |
| Novo Nordisk INC | $19.29 | 2021 | |
| Verrica Pharmaceuticals INC. | $19.18 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $17.16 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.